Author

R. A. DeFronzo

Observed names: R DEFRONZO, Ralph A. DeFronzo

Institutions: The University of Texas at San Antonio Health Science Center, Texas Diabetes Institute

Observed institutions: The University of Texas at San Antonio Health Science Center, Sansum Medical Clinic, Texas Diabetes Institute

OpenAlex ID: A5070534794

Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis

1997 · R DEFRONZO · The Netherlands Journal of Medicine · 280

Insulin resistance and coronary artery disease

1996 · P. Bressler, S. R. Bailey, et al. · Diabetologia · 226

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor

2016 · R. A. DeFronzo, R. Chilton, et al. · Diabetes Obesity and Metabolism · 53

Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome

2006 · R BERRIA, A GASTALDELLI, et al. · Clinical Pharmacology & Therapeutics · 33

High‐density lipoprotein‐cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

2011 · E. Ferrannini, D. J. Betteridge, et al. · Diabetes Obesity and Metabolism · 26

Effect of epinephrine on renal potassium excretion in the isolated perfused rat kidney

1984 · L. D. Katz, J. D'Avella, et al. · American Journal of Physiology-Renal Physiology · 13

Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity

2025 · Anna Ferrulli, Pamela Senesi, et al. · Obesity · 2

Works count: 7

Citation count: 633

H-index: 6

I10-index: 6